KRYSTAL BIOTECH ($KRYS) is expected to release its quarterly earnings data on Monday, August 4th before market open, per Finnhub. Analysts are expecting revenue of $93,795,691 and earnings of $1.16 per share.
You can see Quiver Quantitative's $KRYS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
KRYSTAL BIOTECH Insider Trading Activity
KRYSTAL BIOTECH insiders have traded $KRYS stock on the open market 51 times in the past 6 months. Of those trades, 0 have been purchases and 51 have been sales.
Here’s a breakdown of recent trading of $KRYS stock by insiders over the last 6 months:
- KRISH S KRISHNAN (President and CEO) has made 0 purchases and 25 sales selling 100,000 shares for an estimated $16,407,360.
- SUMA KRISHNAN (President, R&D) has made 0 purchases and 25 sales selling 100,000 shares for an estimated $16,407,360.
- KATHRYN ROMANO (Chief Accounting Officer) sold 750 shares for an estimated $131,415
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
KRYSTAL BIOTECH Hedge Fund Activity
We have seen 147 institutional investors add shares of KRYSTAL BIOTECH stock to their portfolio, and 143 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 365,304 shares (+173.8%) to their portfolio in Q1 2025, for an estimated $65,864,311
- BRAIDWELL LP added 200,244 shares (+99.9%) to their portfolio in Q1 2025, for an estimated $36,103,993
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 185,550 shares (+inf%) to their portfolio in Q1 2025, for an estimated $33,454,665
- BAKER BROS. ADVISORS LP removed 169,934 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $30,639,100
- FRANKLIN RESOURCES INC removed 165,014 shares (-89.7%) from their portfolio in Q1 2025, for an estimated $29,752,024
- 1832 ASSET MANAGEMENT L.P. added 136,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $24,520,800
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 121,702 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $21,942,870
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
KRYSTAL BIOTECH Analyst Ratings
Wall Street analysts have issued reports on $KRYS in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 07/25/2025
- HC Wainwright & Co. issued a "Buy" rating on 07/25/2025
- B of A Securities issued a "Buy" rating on 07/22/2025
- Clear Street issued a "Buy" rating on 07/01/2025
- Guggenheim issued a "Buy" rating on 05/07/2025
- Jefferies issued a "Buy" rating on 03/05/2025
- Cantor Fitzgerald issued a "Overweight" rating on 02/20/2025
To track analyst ratings and price targets for KRYSTAL BIOTECH, check out Quiver Quantitative's $KRYS forecast page.
KRYSTAL BIOTECH Price Targets
Multiple analysts have issued price targets for $KRYS recently. We have seen 9 analysts offer price targets for $KRYS in the last 6 months, with a median target of $192.0.
Here are some recent targets:
- Geulah Livshits from Chardan Capital set a target price of $219.0 on 07/25/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $240.0 on 07/25/2025
- Alec Stranahan from B of A Securities set a target price of $192.0 on 07/22/2025
- Carly Kenselaar from Citigroup set a target price of $176.0 on 07/10/2025
- Bill Maughan from Clear Street set a target price of $190.0 on 07/01/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $189.0 on 05/07/2025
- Roger Song from Jefferies set a target price of $245.0 on 03/05/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
